|
Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
ISSN: 1596-5996 EISSN: 1596-5996
Vol. 14, No. 1, 2015, pp. 141-147
|
Bioline Code: pr15020
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
Tropical Journal of Pharmaceutical Research, Vol. 14, No. 1, 2015, pp. 141-147
en |
Development and Validation of Reverse Phase High Performance Chromatography Method for Determination of Olanzapine in Microsample Rat Plasma: Application to Preclinical Pharmacokinetic Study
Pervaiz, Fahad; Ahmad, Mahmood; Minhas, Muhammad Usman & Sohail, Muhammad
Abstract
Purpose:To develop a sensitive and validated reverse phase-high performance liquid chromatographic (RP-HPLC) method for quantification of olanzapine in micro-sample of rat plasma using UV detection.
Methods: A single oral dose of olanzapine (7 mg/kg) was given to overnight fasted rats (n = 6). Rat
plasma samples containing the drug were extracted by liquid-liquid extraction using a combination of
dichloromethane: n-hexane (80:20). A reverse phase chromatographic column C18 hypersil-BDS was
used for chromatographic separation with a mobile phase consisting of 50 mM phosphate buffer pH 5.5,
acetonitrile and methanol (50:30:20, v/v/v) pumped at a flow rate of 1.2 ml/min. Olanzapine was
measured using ultraviolet (UV) detection at 214 nm. The method was validated for precision and
accuracy.
Results: Separation of compounds of interest was not affected by endogenous interference. Good
linearity within the concentration range of 1 - 500 ng/ml in rat plasma was obtained with coefficient of
regression (r2) of 0.9986. Liquid-liquid extraction produced comparable recovery to solid phase
extraction. Retention time of olanzapine and internal standard (fluoxetine) was 5.0 and 13.4 min,
respectively. Lowest limit of quantification (LLOQ) was 1 ng/ml while inter-day and intra-day precision
was < 12.5 and 5.1 %, respectively. Accuracy of the method was between 94 and 105 % and the
variation of results between two analysts was not significant (p = 0.626). Mean maximum plasma
concentration (Cmax) of olanzapine was 412.7 ng/ml, time to attain maximum plasma concentration
(tmax) was 1 h and half life (t1/2) was 2.54 h.
Conclusion: The proposed method has been successfully validated for precision and accuracy that are
within the limits of U.S. Food and Drug Administration (FDA)’s guidance for bioanalyitcal assay
validation. The method was successfully applied to preclinical pharmacokinetic analysis of olanzapine in
rats
Keywords
Olanzapine; Antipsychotic; Pharmacokinetics; Rat; Plasma; Bioanalytical assay
|
|
© Copyright 2015 - Tropical Journal of Pharmaceutical Research Alternative site location: http://www.tjpr.org
|
|